Retatrutide should not be treated as a stand-alone approach for alcohol cravings or alcohol use disorder
Clinical Trial Results: What the Data Shows Semaglutide has been evaluated in the STEP (Semaglutide Treatment Effect in People with obesity) trial program, which included four major studies of semaglutide 2.4 mg weekly across different patient populations, including adults with obesity, adults with type 2 diabetes, and adults receiving intensive behavioral support alongside the medication
Researchers believe they also have the potential to help patients suffering from a wide variety of other conditions, from addiction to Parkinsons
After at least 30 days at this initial dosage, it can be increased to 7 mg once daily if additional glycemic control is required
Even after quitting GLP-1 treatments, however, youre still getting at least some benefit [with at least 5 percent weight loss], which is great, says Chika Anekwe, an obesity medicine physician at Massachusetts General Hospital Weight Center, but not the entire benefit that you would if you could keep off the majority of the weight. Other studies paint a similar picture
They're both GLP-1 medications
